Just four products are listed as being up for an opinion on whether they should be approved for sale across the EU at the latest meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), under way this week in London.
The CHMP has already adopted a negative opinion on one of the four marketing authorization applications in question – AB...








